Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and non-pregnant, non-lactating females aged 40 or older.~2. Patients with a clinical diagnosis of COPD, according to the GOLD guidelines and stable airway obstruction.~3. Patients with a post-salbutamol FEV1 equal to or greater than 30% of the predicted value and less than 80% of the predicted value~4. Post-salbutamol FEV1/FVC \< 70% at screening visit.~5. Pre-dose FEV1 value of first treatment period within the range of 80-120% of the FEV1 measured at screening prior to salbutamol inhalation.~6. Current, or ex-cigarette smokers (former) with a smoking history of at least 10 pack-years.~7. Patients whose COPD symptoms at the time of randomisation are stable compared to the Screening visit, according to the investigator's medical judgment.~Exclusion Criteria:~1. History or current diagnosis of asthma.~2. A respiratory tract infection or COPD exacerbation in the six weeks prior to the screening visit.~3. Patients who have been hospitalised for an acute COPD exacerbation in the 3 months prior to screening visit.~4. Clinically significant respiratory conditions other than COPD condition.~5. Clinically significant cardiovascular conditions.~6. Patients unable to properly use a dry powder or pMDI inhaler device or unable to perform acceptable spirometry.~7. Clinically relevant abnormalities laboratory, ECG parameters or physical examination results at the screening evaluation that in the investigator's opinion, preclude study participation.~8. Patients who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required washout period for a particular prohibited medication.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm #2 (Type: EXPERIMENTAL): Single dose, double blind treatment period
- Arm #3 (Type: EXPERIMENTAL): Single dose, double blind treatment period
- Arm #4 (Type: EXPERIMENTAL): Single dose, double blind treatment period
- Arm #5 (Type: ACTIVE_COMPARATOR): Single dose, double blind treatment period
- Arm #6 (Type: PLACEBO_COMPARATOR): Single dose, double blind treatment period
- Arm #1 (Type: EXPERIMENTAL): Single dose, double blind treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).